FindTrial
Sign In

A Study of Peldesine (BCX-34) in HIV-Infected Patients

Phase I Placebo-Controlled Study of Oral BCX-34 (Peldesine) in HIV-Infected Patients

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002237
Enrollment
Unknown
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Placebos, Administration, Oral, Anti-HIV Agents, Viral Load, peldesine

Brief summary

The purpose of this study is to determine the highest amount of peldesine that is safe. This study will also see if this amount of peldesine is effective in lowering HIV levels in the blood.

Detailed description

Patients are given either BCX-35 or placebo for 14 or 28 days. Plasma viral load will be determined at the MTD.

Interventions

DRUGPeldesine

Sponsors

BioCryst Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients must have: * Documented HIV infection. * CD4 cell count greater than or equal to 300 cells/mm3 on 3 occasions prior to protocol treatment. * Plasma viral load by Roche Amplicor HIV Monitor assay greater than or equal to 2,000 RNA copies/ml and less than or equal to 50,000 RNA copies/ml on at least 2 occasions prior to protocol treatment. * Normal or non-diagnostic electrocardiogram.

Exclusion criteria

Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Severe opportunistic infection or any other medical condition which in the opinion of the investigators is a contraindication to enrolling in this trial. * Severe lactose intolerance. Concurrent Medication: Excluded: Concomitant therapy with other medications having primary renal excretion (other than 3TC, ddC, and d4T). Prior Medication: Excluded: * Ongoing dideoxyinosine or other antiretroviral therapy except ZDV, 3TC, ddC, d4T, saquinavir, ritonavir, indinavir, and nelfinavir within 2 weeks of study. * Participation in a study of any systemic experimental drug within the last 2 months. Required: \- Ongoing (at least 4 weeks) stable dosage of zidovudine (ZDV) and lamivudine (3TC), ZDV and stavudine (d4T), ZDV and zalcitabine (ddC), d4T and 3TC, ZDV alone, or ddC alone, or in combination with saquinavir, ritonavir, indinavir, or nelfinavir.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026